On Monday, Shares of Archer Daniels Midland Company (NYSE:ADM), added 1.73% and closed at $42.90 in the last trading session. The last trading range of the stock ranges between $41.95 and $42.97. Archer Daniels Midland Company (ADM) declared recently that it has purchased the assets of Caterina Foods, a leading toll manufacturer of specialty gluten-free and high-protein pastas.
“ADM is continuing to deliver on our strategy to create shareholder value by expanding our capabilities downstream in the value chain,” said Vince Macciocchi, president of ADM’s WILD Flavors and Specialty Ingredients business. “Caterina is a toll processor for our majority-owned Harvest Innovations, and will be a key part of our growth plans for that important business. The addition of the Caterina business gives us yet another way in which to meet the needs of health-conscious consumers—in this case expanding our ability to produce specialty pastas from legumes and grains other than wheat.”
Caterina produces gluten-free and high-protein pastas in various shapes and sizes from flours made from corn, lentils, peas, rice, quinoa and many other grains and legumes.
First Horizon National Corp (NYSE:FHN), dropped -0.59% and closed at $15.14 in the last trading session. The last trading range of the stock ranges between $15.02 and $15.25. The company’s Market capitalization is $3.58 Billion with the total Outstanding Shares of 232.02 million. – First Tennessee Bank will contribute $1 million to expand its financial literacy efforts through a partnership with global financial dignity and economic empowerment nonprofit, Operation HOPE, Inc. The $1 million investment in Operation HOPE’s new HOPE Fund will support creation of the First Tennessee Financial Education & Empowerment Program, which will offer free financial education to youth, adults, and small businesses.
The curriculum will be facilitated by First Tennessee’s employee volunteers, planned nonprofit alliance partners, and counselors at First Tennessee HOPE Inside offices.
First Tennessee will open a total of 15 HOPE Inside offices, counting several offices specific to small business counseling. To date, First Tennessee has opened five HOPE Inside offices – in branches in Memphis, Nashville and Knoxville – and will open three more by the end of the year, counting the first HOPE Inside location in Chattanooga. The seven other HOPE Inside offices will open in First Tennessee branches in 2017.
Juno Therapeutics Inc (NASDAQ:JUNO), lost -0.70% and closed at $29.80 in the last trading session. The last trading range of the stock ranges between $28.89 and $30.05. During the 52-week trading session the minimum price at which share price traded, registered at $22.37 and reached to max level of $57.82. Juno Therapeutics, Inc., a biopharmaceutical company, engages in developing cell-based cancer immunotherapies. The company develops cell-based cancer immunotherapies based on its chimeric antigen receptor and T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells. Its clinical stage CD19 product candidates include JCAR015 that is in Phase II clinical trials for adult patients with relapsed/refractory B cell acute lymphoblastic leukemia (r/r ALL); JCAR017, which is in Phase I/II trials for pediatric patients with r/r ALL; and JCAR014 that is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies. The companys additional product candidates comprise CD22, a cell surface protein expressed on B lymphocytes; CD171, a cell-surface adhesion molecule to treat neuroblastoma; MUC-16, a protein for treating ovarian cancers; IL-12, a cytokine to overcome the inhibitory effects; ROR-1, a protein for the treatment of non-small cell lung, triple negative breast, pancreatic, and prostate cancers; and WT-1, an intracellular protein that is in Phase I/II clinical trials to treat adult myeloid leukemia and non-small cell lung, breast, pancreatic, ovarian, and colorectal cancers. Juno Therapeutics, Inc. has partnershipagreements with Celgene Corporation, Editas Medicine, Inc., Fate Therapeutics, Inc., MedImmune Limited, and Memorial Sloan Kettering Cancer Center. The company was formerly known as FC Therapeutics, Inc. and changed its name to Juno Therapeutics, Inc. in October 2013.